NYSE:ENOV Enovis (ENOV) Stock Price, News & Analysis $30.60 -0.42 (-1.36%) Closing price 03:59 PM EasternExtended Trading$30.66 +0.07 (+0.22%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Enovis Stock (NYSE:ENOV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enovis alerts:Sign Up Key Stats Today's Range$30.20▼$31.3050-Day Range$25.74▼$35.9452-Week Range$25.47▼$49.83Volume1.21 million shsAverage Volume1.16 million shsMarket Capitalization$1.75 billionP/E RatioN/ADividend YieldN/APrice Target$51.00Consensus RatingBuy Company Overview Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware. Read More Enovis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreENOV MarketRank™: Enovis scored higher than 91% of companies evaluated by MarketBeat, and ranked 112th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingEnovis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnovis has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Enovis' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth14.34% Earnings GrowthEarnings for Enovis are expected to grow by 14.34% in the coming year, from $2.79 to $3.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enovis is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enovis is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnovis has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Enovis' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.30% of the float of Enovis has been sold short.Short Interest Ratio / Days to CoverEnovis has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Enovis has recently decreased by 7.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnovis does not currently pay a dividend.Dividend GrowthEnovis does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.30% of the float of Enovis has been sold short.Short Interest Ratio / Days to CoverEnovis has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Enovis has recently decreased by 7.40%, indicating that investor sentiment is improving significantly. News and Social Media4.1 / 5News Sentiment1.47 News SentimentEnovis has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.02 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Enovis this week, compared to 6 articles on an average week.Search Interest1 people have searched for ENOV on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Enovis to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Enovis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $174,787.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of Enovis is held by insiders.Percentage Held by Institutions98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enovis' insider trading history. Receive ENOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENOV Stock News HeadlinesEnovis (NYSE:ENOV) CFO Buys $74,275.00 in StockAugust 21, 2025 | insidertrades.comEnovis: Healthy Recon Trends Vs. Market ApathyAugust 27 at 8:24 AM | seekingalpha.comSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split the entire U.S. market in two on or before Sept 30, causing a crisis "many times worse than 2008."August 28 at 2:00 AM | Altimetry (Ad)Spotting Winners: Enovis (NYSE:ENOV) And Medical Devices & Supplies - Specialty Stocks In Q2August 27 at 6:05 AM | msn.comFinancial Comparison: Health Catalyst (NASDAQ:HCAT) vs. Enovis (NYSE:ENOV)August 26 at 2:33 AM | americanbankingnews.comHoneywell Names Board of Directors for Solstice Advanced Materials SpinoffAugust 23, 2025 | marketwatch.comEnovis (NYSE:ENOV) Shares Gap Up - Time to Buy?August 17, 2025 | americanbankingnews.comWells Fargo Sticks to Its Buy Rating for Enovis (ENOV)August 17, 2025 | theglobeandmail.comSee More Headlines ENOV Stock Analysis - Frequently Asked Questions How have ENOV shares performed this year? Enovis' stock was trading at $43.88 at the beginning of 2025. Since then, ENOV stock has decreased by 30.3% and is now trading at $30.5970. How were Enovis' earnings last quarter? Enovis Corporation (NYSE:ENOV) announced its quarterly earnings data on Thursday, August, 7th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.05. The firm's revenue was up 7.5% on a year-over-year basis. Read the conference call transcript. Who are Enovis' major shareholders? Top institutional investors of Enovis include DAVENPORT & Co LLC (4.98%), Hood River Capital Management LLC (3.04%), River Road Asset Management LLC (2.52%) and Boston Partners (2.42%). Insiders that own company stock include Matthew L Trerotola, Phillip Benjamin (Ben) Berry, Daniel A Pryor, Brady Shirley, Christopher M Hix, Bradley J Tandy, A Clayton Perfall, Patricia A Lang, Rajiv Vinnakota and John Kleckner. View institutional ownership trends. How do I buy shares of Enovis? Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enovis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enovis investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings8/07/2025Today8/28/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MEDICAL INFO SYS Sub-IndustryMedical Equipment Current SymbolNYSE:ENOV CIK1420800 Webwww.enovis.com Phone302-252-9160Fax301-323-9001Employees7,367Year FoundedN/APrice Target and Rating Average Price Target for Enovis$51.00 High Price Target$58.00 Low Price Target$41.00 Potential Upside/Downside+66.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($14.25) Trailing P/E Ratio9.37 Forward P/E Ratio10.97 P/E GrowthN/ANet Income-$825.49 million Net Margins-37.80% Pretax Margin-36.51% Return on Equity6.78% Return on Assets3.73% Debt Debt-to-Equity Ratio0.53 Current Ratio2.25 Quick Ratio1.15 Sales & Book Value Annual Sales$2.11 billion Price / Sales0.83 Cash Flow$19.00 per share Price / Cash Flow1.61 Book Value$45.15 per share Price / Book0.68Miscellaneous Outstanding Shares57,160,000Free Float55,617,000Market Cap$1.75 billion OptionableOptionable Beta1.70 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSE:ENOV) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Enovis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.